biotech / news / / Artvoice
A Phase 2 clinical trial has begun enrolling patients in the United States for an experimental immunotherapy.
The Phase 1 SYNC-T trial in Mexico reported an 87% tumor response rate in metastatic prostate cancer.
KEY POINTS
- SYNC-T therapy uniquely combines cryoablation with four immunotherapy agents injected directly into tumors.
- The Phase 2 LEGION-100 trial is now enrolling US patients under FDA Fast Track designation as of July 2024.
- Dr. Jason Williams, originator of SYNC-T, is not listed in Syncromune’s leadership despite developing the protocol.
- No severe immune-related side effects observed in Phase 1, with some patients showing complete remission of bone metastases.
COMPANIES
Summarized by Newsio from Artvoice. How we summarize →